CancerDrs Find care

Liver Cancer clinical trials in Louisiana

10 actively recruiting liver cancer trials at 5 sites across Louisiana.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…

Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Louisiana:
  • Research Site — Shreveport, Louisiana
Phase 3 Recruiting Industry

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…

Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Louisiana:
  • Louisiana State University Health Sciences — Metairie, Louisiana
Phase 2 Recruiting Industry

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…

Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Louisiana:
  • LSU Health Baton Rouge — Baton Rouge, Louisiana
  • Our Lady of the Lake Cancer Institute — Baton Rouge, Louisiana
Phase 2 Recruiting NIH

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Louisiana:
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting Academic/Other

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unr…

Sponsor: Academic and Community Cancer Research United
NCT ID: NCT05168163
Sites in Louisiana:
  • University Medical Center New Orleans — New Orleans, Louisiana
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana:
  • Massive Bio SYNERGY-AI site — New Orleans, Louisiana
Recruiting Industry

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristic…

Sponsor: HistoSonics, Inc.
NCT ID: NCT06486454
Sites in Louisiana:
  • Willis Knighton Health — Shreveport, Louisiana
Recruiting Industry

Observational Study Protocol: LIVER-R

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multi…

Sponsor: AstraZeneca
NCT ID: NCT06252753
Sites in Louisiana:
  • Research Site — Baton Rouge, Louisiana
NA Recruiting Academic/Other

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization …

Sponsor: Ochsner Health System
NCT ID: NCT05953961
Sites in Louisiana:
  • Ochsner Main Campus — New Orleans, Louisiana

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20